65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Weighted Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 0-24 Hours at Week 12 for Modified Per Protocol (mPP) Population — 0.045; 0.030…
Chondrosarcoma · Metastatic Chondrosarcoma
Primary: Disease Control at Week 16 — 43 Percentage of CR+PR+SD
Alzheimer's Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 89.4; 90.5; 96.0; 87.9 percentage of participants
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Drug Overdose · Virtual Reality
Primary: Change in Opioid Overdose Knowledge Scale (OOKS) From Pre- to Post-training — 2; 1 units on a scale — p=0.65
Atrial Fibrillation
Primary: Event Rate of Stroke/Systemic Embolism Requiring Hospitalization: NOAC Versus Warfarin Analysis — 7.66; 13.52; 7.2; 13.53 events per 100 participants-years
Scleroderma · Systemic Sclerosis
Primary: Participant Feedback on Usability of Program Materials — 10 Participants
Breast Cancer
Primary: Maximum Tolerated Dose — 21 Gray (Gy)
Diabetes Mellitus, Type 2
Primary: Percent of Participants With Adherence to the PDTA — 98; 98; 98 percentage of participants
Peritonitis
Primary: Heart Rate — 108.18 Beats/min
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
Endothelial Dysfunction
Primary: Percent Change in Flow Mediated Dilation — 12.3; 11.6; 10.9; 11.1 percent change
Phototoxicity
Primary: Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream…
Hypothermia
Primary: Intraoperative Change in Body Core Temperature — 35.73; 35.70; 35.78; 35.77 degrees °C
Obesity
Primary: Change in Body Weight — 6.5; 7.5 percentage weight loss — p=<0.05